Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prochlorperazine inhalation - Alexza Pharmaceuticals

Drug Profile

Prochlorperazine inhalation - Alexza Pharmaceuticals

Alternative Names: AZ-001; Staccato prochlorperazine

Latest Information Update: 23 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexza Pharmaceuticals
  • Class Antiemetics; Antipsychotics; Phenothiazines; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Nov 2009 Prochlorperazine is still available for partnering (http://www.alexza.com)
  • 26 Mar 2007 Final efficacy and adverse events data from a phase IIb trial migraine released by Alexza Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top